Trial: 201301106

A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 inhibitor, in Combination with Anastrozole in Women with Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Phase

II

Principal Investigator

Ma, Cynthia

Disease Site

Breast

Learn more about this study at: clinicaltrials.gov